tetano
Editor, Senior Moderator
J Med Virol
. 2021 Aug 17.
doi: 10.1002/jmv.27274. Online ahead of print.
Anti-SARS-CoV-2 IgG levels in relation to disease severity of COVID-19
Xiquan Yan[SUP] 1 2 [/SUP], Guoqiang Chen[SUP] 3 [/SUP], Zhaoxia Jin[SUP] 4 [/SUP], Zhongwei Zhang[SUP] 1 [/SUP], Bing Zhang[SUP] 3 [/SUP], Jiangming He[SUP] 5 [/SUP], Siqing Yin[SUP] 5 [/SUP], Juanshu Huang[SUP] 6 [/SUP], Maiying Fan[SUP] 1 [/SUP], Zhenyuan Li[SUP] 1 [/SUP], Fang Chen[SUP] 1 [/SUP], Yong Zeng[SUP] 7 [/SUP], Xiaotong Han[SUP] 1 [/SUP], Yimin Zhu[SUP] 1 2 [/SUP]
Affiliations
Abstract
The durability of infection-induced severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunity has crucial implications for reinfection and vaccine effectiveness. However, the relationship between coronavirus disease 2019 (COVID-19) severity and long-term anti-SARS-CoV-2 IgG antibody level is poorly understood. Here, we measured the longevity of SARS-CoV-2-specific IgG antibodies in survivors who had recovered from COVID-19 1 year previously. In a cohort of 473 survivors with varying disease severity (asymptomatic, mild, moderate, or severe), we observed a positive correlation between virus-specific IgG antibody titers and COVID-19 severity. In particular, the highest virus-specific IgG antibody titers were observed in patients with severe COVID-19. By contrast, 74.4% of recovered asymptomatic carriers had negative anti-SARS-CoV-2 IgG test results, while many others had very low virus-specific IgG antibody titers. Our results demonstrate that SARS-CoV-2-specific IgG persistence and titer depend on COVID-19 severity. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; IgG; SARS-CoV-2; disease severity; serology.
. 2021 Aug 17.
doi: 10.1002/jmv.27274. Online ahead of print.
Anti-SARS-CoV-2 IgG levels in relation to disease severity of COVID-19
Xiquan Yan[SUP] 1 2 [/SUP], Guoqiang Chen[SUP] 3 [/SUP], Zhaoxia Jin[SUP] 4 [/SUP], Zhongwei Zhang[SUP] 1 [/SUP], Bing Zhang[SUP] 3 [/SUP], Jiangming He[SUP] 5 [/SUP], Siqing Yin[SUP] 5 [/SUP], Juanshu Huang[SUP] 6 [/SUP], Maiying Fan[SUP] 1 [/SUP], Zhenyuan Li[SUP] 1 [/SUP], Fang Chen[SUP] 1 [/SUP], Yong Zeng[SUP] 7 [/SUP], Xiaotong Han[SUP] 1 [/SUP], Yimin Zhu[SUP] 1 2 [/SUP]
Affiliations
- PMID: 34403142
- DOI: 10.1002/jmv.27274
Abstract
The durability of infection-induced severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunity has crucial implications for reinfection and vaccine effectiveness. However, the relationship between coronavirus disease 2019 (COVID-19) severity and long-term anti-SARS-CoV-2 IgG antibody level is poorly understood. Here, we measured the longevity of SARS-CoV-2-specific IgG antibodies in survivors who had recovered from COVID-19 1 year previously. In a cohort of 473 survivors with varying disease severity (asymptomatic, mild, moderate, or severe), we observed a positive correlation between virus-specific IgG antibody titers and COVID-19 severity. In particular, the highest virus-specific IgG antibody titers were observed in patients with severe COVID-19. By contrast, 74.4% of recovered asymptomatic carriers had negative anti-SARS-CoV-2 IgG test results, while many others had very low virus-specific IgG antibody titers. Our results demonstrate that SARS-CoV-2-specific IgG persistence and titer depend on COVID-19 severity. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; IgG; SARS-CoV-2; disease severity; serology.